KISHIDA CHEMICAL, PeptiDream Inc., Fujitsu Limited, Mizuho Capital Co., Ltd. which is a consolidated subsidiary of Mizuho Financial Group, Inc., and Takenaka Corporation have agreed today to establish PeptiAID Inc., a joint venture company that will research and develop peptide therapeutics capable of neutralizing both the current SARS-CoV-2 virus (Coronavirus Disease "COVID-19") and potentially any future Coronavirus outbreaks that may occur.
If you know more information, please kindly find attached file.
PeptiAID_Press+English_PD.pdf
Thank you
]]>